237 related articles for article (PubMed ID: 34788412)
1. Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
Reddy VR; Pepper RJ; Shah K; Cambridge G; Henderson SR; Klein C; Kell L; Taylor SJ; Isenberg DA; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2022 Jul; 61(7):2894-2904. PubMed ID: 34788412
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
3. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
4. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.
Mota P; Reddy V; Isenberg D
Expert Rev Clin Immunol; 2017 Jul; 13(7):667-676. PubMed ID: 27841031
[TBL] [Abstract][Full Text] [Related]
5. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Reddy V; Dahal LN; Cragg MS; Leandro M
Drug Discov Today; 2016 Aug; 21(8):1330-8. PubMed ID: 27343722
[TBL] [Abstract][Full Text] [Related]
6. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
Arnold J; Dass S; Twigg S; Jones CH; Rhodes B; Hewins P; Chakravorty M; Courtney P; Ehrenstein M; Md Yusof MY; Vital EM
Rheumatology (Oxford); 2022 Nov; 61(12):4905-4909. PubMed ID: 35266512
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
Kraaij T; Arends EJ; van Dam LS; Kamerling SWA; van Daele PLA; Bredewold OW; Ray A; Bakker JA; Scherer HU; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1474-1483. PubMed ID: 32591783
[TBL] [Abstract][Full Text] [Related]
9. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
10. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
11. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.
Bekar KW; Owen T; Dunn R; Ichikawa T; Wang W; Wang R; Barnard J; Brady S; Nevarez S; Goldman BI; Kehry M; Anolik JH
Arthritis Rheum; 2010 Aug; 62(8):2443-57. PubMed ID: 20506300
[TBL] [Abstract][Full Text] [Related]
12. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
13. Patients with systemic lupus erythematosus show increased proportions of CD19
Zhu Q; Li Y; Zhang L; Wang M; Chen Z; Shi J; Li J; Li B; Li Z; Wang Y; Xie C
Clin Rheumatol; 2021 Jan; 40(1):151-165. PubMed ID: 32542581
[TBL] [Abstract][Full Text] [Related]
14. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
15. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Furie RA; Aroca G; Cascino MD; Garg JP; Rovin BH; Alvarez A; Fragoso-Loyo H; Zuta-Santillan E; Schindler T; Brunetta P; Looney CM; Hassan I; Malvar A
Ann Rheum Dis; 2022 Jan; 81(1):100-107. PubMed ID: 34615636
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
18. Longer duration of B cell depletion is associated with better outcome.
Dias SS; Rodriguez-Garcia V; Nguyen H; Pericleous C; Isenberg D
Rheumatology (Oxford); 2015 Oct; 54(10):1876-81. PubMed ID: 26044042
[TBL] [Abstract][Full Text] [Related]
19. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
Bela MM; Espinosa G; Cervera R
Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
[No Abstract] [Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
